Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 166 clinical trials
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

-based induction chemotherapy with pembrolizumab. The primary hypotheses are: participants with confirmed diagnosis of NSCLC could benefit from niraparib plus pembrolizumab versus placebo plus

lung carcinoma
pembrolizumab
cancer chemotherapy
chemoradiotherapy
  • 16 views
  • 29 Dec, 2021
  • 142 locations
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients 60 Years Old

The study will include newly-diagnosed AML patients, not suffering acute promyelocytic leukemia; aged 18-60 years, who are eligible for standard induction chemotherapy. The patients will be

acute promyelocytic leukemia
remission
secondary acute myeloid leukemia
myelodysplastic syndromes
ara-c
  • 32 views
  • 07 Oct, 2021
  • 10 locations
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

>To compare a single dose of gemtuzumab ozogamicin with the optimum tolerated number of doses of gemtuzumab ozogamicin (identified by the dose-finding study) when combined with induction

remission
fludarabine
flow cytometry
anthracyclines
ara-c
  • 0 views
  • 26 Jan, 2022
  • 69 locations
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative

mycn protein
filgrastim
etoposide
interleukin
isotretinoin
  • 308 views
  • 26 Jan, 2021
  • 126 locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the

fludarabine
pegaspargase
mercaptopurine
etoposide
methotrexate
  • 870 views
  • 13 Feb, 2022
  • 93 locations
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer (FANTASTIC)

adjuvant chemotherapy to preoperative neoadjuvant therapy due to low compliance of adjuvant chemotherapy. During neoadjuvant treatment, induction chemotherapy with FOLFOX / CAPEOX or consolidation

oxaliplatin
adjuvant therapy
fluorouracil
cancer surgery
colon cancer
  • 0 views
  • 04 Mar, 2022
  • 1 location
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

  • 17 views
  • 12 May, 2022
  • 17 locations
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells …

remission
cell transplantation
chop regimen
monoclonal antibodies
vincristine
  • 367 views
  • 31 Jan, 2022
  • 238 locations
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia. The study has two parts: Part 1 to define the Recommended Phase 2 Dose, and Part 2 to evaluate safety and tolerability and efficacy …

  • 31 views
  • 19 Jun, 2022
  • 23 locations
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: Venetoclax and azacitidine (investigational combination) Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin …

myelodysplasia
hydroxyurea
venetoclax
gilbert's syndrome
cytarabine
  • 0 views
  • 26 Mar, 2022
  • 2 locations